RichardJaebongLeeMDPhD

PubMed

• 2 citations
  Circulating Tumor Cells and Circulating Tumor DNA in Urologic Cancers.
  Ikenna Madueke, Richard J Lee, David T Miyamoto> ;The Urologic Clinics of North America. 2023 Feb 1
• 32 citations
  Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical Trial.
  Nizar M Tannir, Neeraj Agarwal, Camillo Porta, Nicola J Lawrence, Robert Motzer, Bradley McGregor, Richard J Lee, Rohit K Jain, Nancy Davis, Leonard J Appleman, Oscar ...> ;JAMA Oncology. 2022 Oct 1
• 2 citations
  Phase II trial of CV301 vaccine combined with atezolizumab in advanced urothelial carcinoma.
  Guru P Sonpavde, Benjamin Louis Maughan, Bradley Alexander McGregor, Xiao X Wei, Kerry L Kilbridge, Richard J Lee, Evan Y Yu, Michael Thomas Schweizer, Robert B Montgo...> ;Cancer Immunology, Immunotherapy. 2023 Mar 1
• 2 citations
  Charting a Path Towards Asian American Cancer Health Equity: A Way Forward.
  Moon S Chen, Richard J Lee, Ravi A Madan, Van Ta Park, Susan M Shinagawa, Tracy Sun, Scarlett L Gomez> ;Journal of the National Cancer Institute. 2022 Jun 13
• 3 citations
  Multicancer Early Detection Technologies: A Review Informed by Past Cancer Screening Studies.
  Sana Raoof, Richard J Lee, Kunal Jajoo, Joseph D Mancias, Timothy R Rebbeck, Steven J Skates> ;Cancer Epidemiology, Biomarkers & Prevention. 2022 Jun 1
• 20 citations
  Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial.
  Funda Meric-Bernstam, Nizar M Tannir, Othon Iliopoulos, Richard J Lee, Melinda L Telli, Alice C Fan, Angela DeMichele, Naomi B Haas, Manish R Patel, James J Harding, M...> ;Clinical Cancer Research. 2022 Apr 14
• 28 citations
  Current Status of MRI and PET in the NCCN Guidelines for Prostate Cancer.
  Brandon R Mason, James A. Eastham, Brian J. Davis, Lance A. Mynderse, Thomas J. Pugh, Richard T. Lee, Joseph E. Ippolito> ;Journal of the National Comprehensive Cancer Network. 2019 May 1
• The evolution and understanding of skeletal complication endpoints in clinical trials of tumors with metastasis to the bone.
  Hussain, A.,Lee, R. J.,Graff, J. N.,Halabi, S.> ;Crit. Rev. Oncol. Hematol.. 2019 Jun 07
• Prostate cancer in transgender women.
  Ingham, M. D.,Lee, R. J.,MacDermed, D.,Olumi, A. F.> ;Urol. Oncol.. 2018 Oct 17
• 25 citations
  Branched Chain RNA In Situ Hybridization for Androgen Receptor Splice Variant AR-V7 as a Prognostic Biomarker for Metastatic Castration-Sensitive Prostate Cancer
  Philip J. Saylor, Richard T. Lee, Kshitij S. Arora, Vikram Deshpande, Rong Hu, Kara M. Olivier, Erika Meneely, Miguel Rivera, David T. Ting, Chin-Lee Wu, David T. Miya...> ;Clinical Cancer Research. 2017 Jan 15
• Clinical Outcomes of Patients with Histologic Variants of Urothelial Cancer Treated with Trimodality Bladder-sparing Therapy.
  Krasnow, R. E.,Drumm, M.,Roberts, H. J.,Niemierko, A.,Wu, C. L.,Wu, S.,Zhang, J.,Heney, N. M.,Wszolek, M. F.,Blute, M. L.,Feldman, A. S.,Lee, R. J.,Zietman, A. L.,Ship...> ;Eur. Urol.. 2017 Jan 04
• Circulating tumour cells-monitoring treatment response in prostate cancer.
  Miyamoto, D. T.,Sequist, L. V.,Lee, R. J.> ;Nat Rev Clin Oncol. 2014 May 14
• Cabozantinib and prostate cancer: inhibiting seed and disrupting soil?
  Lee, R. J.,Smith, M. R.> ;Clin. Cancer Res.. 2013 Nov 29
• A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases.
  Lee, R. J.,Saylor, P. J.,Michaelson, M. D.,Rothenberg, S. M.,Smas, M. E.,Miyamoto, D. T.,Gurski, C. A.,Xie, W.,Maheswaran, S.,Haber, D. A.,Goldin, J. G.,Smith, M. R.> ;Clin. Cancer Res.. 2013 Jun 1
• Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells.
  Ozkumur, E.,Shah, A. M.,Ciciliano, J. C.,Emmink, B. L.,Miyamoto, D. T.,Brachtel, E.,Yu, M.,Chen, P. I.,Morgan, B.,Trautwein, J.,Kimura, A.,Sengupta, S.,Stott, S. L.,Ka...> ;Sci Transl Med. 2013 Apr 3
• Trimodality Therapy for Bladder Conservation in Treatment of Invasive Bladder Cancer.
  Mitin, T.,Shipley, W. U.,Efstathiou, J. A.,Heney, N. M.,Kaufman, D. S.,Lee, R. J.,Zietman, A. L.> ;Curr Urol Rep. 2013 Apr
• Patients with Testicular Cancer Undergoing CT Surveillance Demonstrate a Pitfall of Radiation-Induced Cancer Risk Estimates: The Timing Paradox
  Mannudeep K Kalra, G Scott Gazelle, Jonathan D Eisenberg, Richard J Lee> ;Radiology. 2013 Mar
• Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer.
  Michaelson, M. D., Bellmunt, J., Hudes, G. R., Goel, S., Lee, R. J., Kantoff, P. W., Stein, C. A., Lardelli, P., Pardos, I., Kahatt, C., Nieto, A., Cullell-Young, M., ...> ;Ann Oncol. 2012 May
• Treatment and prevention of bone complications from prostate cancer.
  Lee, R. J.,Saylor, P. J.,Smith, M. R.> ;Bone. 2010 Jul 14
• Contemporary therapeutic approaches targeting bone complications in prostate cancer.
  Lee, R. J.,Saylor, P. J.,Smith, M. R.> ;Clin Genitourin Cancer. 2011 Jan 07
• Application of a fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancer.
  Saylor PJ, Kaufman DS, Michaelson MD, Lee RJ, Smith MR> ;J. Urol.. 2010-06-01
• Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer.
  Stott SL, Lee RJ, Nagrath S, Yu M, Miyamoto DT, Ulkus L, Inserra EJ, Ulman M, Springer S, Nakamura Z, Moore AL, Tsukrov DI, Kempner ME, Dahl DM, Wu C, Iafrate AJ, Smit...> ;Sci Transl Med. 2010-03-31
• Join now to see all